Alum

BIOLOGICAL4 trials

Sponsors

Novartis Pharmaceuticals, Vaxine Pty Ltd, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Alzheimer's DiseaseAlzheimers DiseaseExposure to Hepatitis B VirusHIV Infections

Phase 1

Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine

CompletedNCT01951677

Vaxine Pty LtdExposure to Hepatitis B Virus

Start: 2013-07-31End: 2019-05-31Target: 240Updated: 2019-05-07

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

CompletedNCT05781542

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2023-04-10End: 2025-04-14Updated: 2025-11-14

Phase 2

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

CompletedNCT01097096

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2010-03-31End: 2012-12-31Updated: 2021-03-05

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

TerminatedNCT02565511

Novartis PharmaceuticalsAlzheimers Disease

Start: 2015-11-30End: 2020-04-30Updated: 2021-07-08

Related Papers

Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1.

2025-11-27

P4‐654: CONNECT 4 <i>APOE</i>: A RANDOMIZED STUDY OF PHONE VERSUS VIDEOCONFERENCE DELIVERY OF <i>APOE</i> GENOTYPE DISCLOSURE IN THE GENERATION STUDY

Alzheimer s & Dementia2019-07-011 citations

The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease.

2017-01-0126 citations